Pfizer to acquire Biohaven in ~$11.6B deal; Biohaven stock soars 72%

May 10, 2022 7:22 AM ETBiohaven Ltd. (BHVN)By: Ravikash, SA News Editor26 Comments

word M and A made with wood building blocks, concept

Maks_Lab/iStock via Getty Images

Pfizer (NYSE:PFE) is acquiring Biohaven (NYSE:BHVN) for a total of ~$11.6B in cash.

The two companies have been partners for migraine therapy rimegepant, sold as NURTEC ODT, and zavegepant. Pfizer had previously invested $350M to acquire 2.6% stake in Biohaven at $173 per

Recommended For You

Comments (26)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.